Background: Primary refractory (PREF) follicular lymphoma (FL) has a completely different clinical course from that of FL that responds to front-line treatments. In addition to having poor responses to salvage therapies, it seems that patients with PREF are at increased risk of histological transformation (HT). The Aristotle consortium presented the opportunity of investigating the risk of HT in a very large series of cases. Thus, we investigated the risk of HT in patients with PREF FL compared with that of responding patients or in stable disease and ultimately their outcome. Methods: Six thousand three hundred thirty-nine patients from the Aristotle database were included in the analysis. These patients had a histologically confirmed grad...
Abstract Population-based data comparing the outcomes of patients with transformed follicular lympho...
The transformation of follicular lymphoma to an aggressive lymphoma is a well-recognised complicatio...
Introduction: Treatment of transformed follicular lymphoma (TFL) is diverse as there are no randomiz...
Background: Primary refractory (PREF) follicular lymphoma (FL) has a completely different clinical c...
The diagnostic criteria for follicular lymphoma (FL) transformation vary among the largest series, w...
Background: Histological transformation of follicular lymphoma to aggressive lymphoma is a serious e...
Transformation of follicular lymphoma (FL) into aggressive disease and relapse of de novo diffuse la...
PurposeTo study the clinical significance of transformation to diffuse large B-cell lymphoma (DLBCL)...
Purpose: To study the outcome of histologic transformation (HT) in a large prospective cohort of pat...
The natural history of follicular lymphoma is heterogeneous with numerous relapses and remissions ov...
Although follicular lymphoma (FL) patients relapsing within 24 months after first-line treatment (PO...
Follicular Lymphoma (FL) is the second most common type of non-Hodgkin lymphoma and is considered to...
Optimal treatment for transformed follicular lymphoma (tFL) is not fully defined. Clinical character...
Although the introduction of immunotherapy has improved outcomes for follicular lymphoma (FL) patien...
Purpose: We previously reported that ∼30% of patients with localized follicular lymphoma (FL)staged ...
Abstract Population-based data comparing the outcomes of patients with transformed follicular lympho...
The transformation of follicular lymphoma to an aggressive lymphoma is a well-recognised complicatio...
Introduction: Treatment of transformed follicular lymphoma (TFL) is diverse as there are no randomiz...
Background: Primary refractory (PREF) follicular lymphoma (FL) has a completely different clinical c...
The diagnostic criteria for follicular lymphoma (FL) transformation vary among the largest series, w...
Background: Histological transformation of follicular lymphoma to aggressive lymphoma is a serious e...
Transformation of follicular lymphoma (FL) into aggressive disease and relapse of de novo diffuse la...
PurposeTo study the clinical significance of transformation to diffuse large B-cell lymphoma (DLBCL)...
Purpose: To study the outcome of histologic transformation (HT) in a large prospective cohort of pat...
The natural history of follicular lymphoma is heterogeneous with numerous relapses and remissions ov...
Although follicular lymphoma (FL) patients relapsing within 24 months after first-line treatment (PO...
Follicular Lymphoma (FL) is the second most common type of non-Hodgkin lymphoma and is considered to...
Optimal treatment for transformed follicular lymphoma (tFL) is not fully defined. Clinical character...
Although the introduction of immunotherapy has improved outcomes for follicular lymphoma (FL) patien...
Purpose: We previously reported that ∼30% of patients with localized follicular lymphoma (FL)staged ...
Abstract Population-based data comparing the outcomes of patients with transformed follicular lympho...
The transformation of follicular lymphoma to an aggressive lymphoma is a well-recognised complicatio...
Introduction: Treatment of transformed follicular lymphoma (TFL) is diverse as there are no randomiz...